65658 Federal Register / Vol. 75, No. 206 / Tuesday, October 26, 2010 / Notices 

transfer its holdings to a successor 

organization or is itself designated the 

permanent custodian of the intellectual 

property. 

Below is the name and contact 

information of an individual from 

whom additional information 

concerning the organization can be 

obtained: Carey R. Ramos, Esq.; Paul, 

Weiss, Rifkind, Wharton & Garrison 

LLP; 1285 Avenue of the Americas; New 

York, NY 10019–6064. 

Patricia A. Brink, 

Deputy Director of Operations, Antitrust 

Division. 

[FR Doc. 2010–26734 Filed 10–25–10; 8:45 am] 

BILLING CODE 4410–11–M 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled 

Substances;Notice of Application 

This is notice that on July 22, 2010, 

Cody Laboratories Inc., 601 Yellowstone 

Avenue, Cody, Wyoming 82414–9321, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) for registration as an importer of 

the basic classes of controlled 

substances listed in schedule II: 

Drug Schedule 

Raw Opium (9600) ....................... II 

Concentrate of Poppy Straw 

(9670).

II 

The company plans to import narcotic 

raw materials for manufacturing and 

further distribution to its customers. 

The company is registered with DEA as 

a manufacturer of several controlled 

substances that are manufactured from 

raw opium, poppy straw, and 

concentrate of poppy straw. 

As explained in the Correction to 

Notice of Application pertaining to 

Rhodes Technologies, 72 FR 3417 

(2007), comments and requests for 

hearings on applications to import 

narcotic raw material are not 

appropriate. 

As noted in a previous notice 

published in the Federal Register on 

September 23, 1975, (40 FR 43745), all 

applicants for registration to import a 

basic class of any controlled substances 

in schedule I or II are, and will continue 

to be, required to demonstrate to the 

Deputy Assistant Administrator, Office 

of Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: October 19, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator,Office of 

Diversion Control,Drug Enforcement 

Administration. 

[FR Doc. 2010–27023 Filed 10–25–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to Title 21 Code of Federal 

Regulations 1301.34(a), this is notice 

that on July 12, 2010, Noramco, Inc., 

Division of Ortho-McNeil, Inc., 500 

Swedes Landing Road, Wilmington, 

Delaware 19801, made application by 

renewal to the Drug Enforcement 

Administration (DEA) for registration as 

an importer of the basic classes of 

controlled substances listed in schedule 

II: 

Drug Schedule 

Raw Opium (9600) ....................... II 

Concentrate of Poppy Straw 

(9670).

II 

Tapentadol (9780) ........................ II 

The company plans to import the Raw 

Opium (9600) and Concentrate of Poppy 

Straw (9670) to manufacture other 

controlled substances. The company 

plans to import Tapentadol (9780) in 

intermediate form for the bulk 

manufacture of Tapentadol (9780) 

which it will distribute to its customers. 

No comments, objections, or requests 

for any hearings will be accepted on any 

application for registration or reregistration to import crude opium, 

poppy straw, concentrate of poppy 

straw, and coca leaves. As explained in 

the Correction to Notice of Application 

pertaining to Rhodes Technologies, 72 

FR 3417 (2007), comments and requests 

for hearings on applications to import 

narcotic raw material are not 

appropriate. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic classes of controlled 

substances listed in schedule I or II, 

which fall under the authority of section 

1002(a)(2)(B) of the Act [21 U.S.C. 

952(a)(2)(B)] may, in the circumstances 

set forth in 21 U.S.C. 958(i), file 

comments or objections to the issuance 

of the proposed registration and may, at 

the same time, file a written request for 

a hearing on such application pursuant 

to 21 CFR 1301.43 and in such form as 

prescribed by 21 CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 26, 2010. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745–46), all applicants for 

registration to import a basic class of 

any controlled substances in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 

21U.S.C. 958(a); 21 U.S.C. 823(a); and 

21 CFR 1301.34(b), (c), (d), (e), and (f) 

are satisfied. 

Dated: October 19, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator,Office of 

Diversion Control,Drug Enforcement 

Administration. 

[FR Doc. 2010–27025 Filed 10–25–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on July 12 2010, 

Aldrich Chemical Company Inc., DBA 

Isotec, 3858 Benner Road, Miamisburg, 

Ohio 45342–4304, made application by 

renewal to the Drug Enforcement 

Administration (DEA) as a bulk 

manufacturer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

Gamma Hydroxybutyric Acid 

(2010).

I 

Methaqualone (2565) ................... I 

Ibogaine (7260) ............................ I 

Tetrahydrocannabinols (7370) ..... I 

2,5–Dimethoxyamphetamine 

(7396).

I 

Psilocyn (7438) ............................. I 

Normorphine (9313) ..................... I 

Acetylmethadol (9601) ................. I 

Alphacetylmethadol except levo– 

alphacetylmethadol (9603).

I 

Normethadone (9635) .................. I 

Norpipanone (9636) ..................... I 

3–Methylfentanyl (9813) ............... I 


emcdonald on DSK2BSOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 206 / Tuesday, October 26, 2010 / Notices 65659 

Drug Schedule 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Methylphenidate (1724) ................ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

1–Phenylcyclohexylamine (7460) II 

Phencyclidine (7471) .................... II 

Phenylacetone (8501) .................. II 

1– 

Piperidinocyclohexanecarbonitrile (8603).

II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Benzoylecgonine (9180) ............... II 

Ethylmorphine (9190) ................... II 

Hydrocodone (9193) ..................... II 

Isomethadone (9226) ................... II 

Meperidine (9230) ........................ II 

Meperidine intermediate-A (9232) II 

Meperidine intermediate-B (9233) II 

Methadone (9250) ........................ II 

Methadone intermediate (9254) ... II 

Dextropropoxyphene, bulk, (nondosage forms) (9273).II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Levo-alphacetylmethadol (9648) .. II 

Oxymorphone (9652) ................... II 

The company plans to manufacture 

small quantities of the listed controlled 

substances to produce isotope labeled 

standards for drug testing and analysis. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than December 27, 2010. 

Dated: October 19, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–27018 Filed 10–25–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances;Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on September 8, 2009 

Cedarburg Pharmaceuticals, Inc., 870 

Badger Circle, Grafton, Wisconsin 

53024, made application by renewal to 

the Drug Enforcement Administration 

(DEA) as a bulk manufacturer of the 

basic classes of controlled substances 

listed in schedules I and II: 

Drug Schedule 

Tetrahydrocannabinols (7370) ..... I 

Dihydromorphine (9145) ............... I 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Hydrocodone (9193) ..................... II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

In reference to drug code 7370 the 

company plans to bulk manufacture a 

synthetic Tetrahydrocannabinol. No 

other activity for this drug is authorized 

for this registration. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than December 27, 2010. 

Dated: October 19, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator,Office of 

Diversion Control,Drug Enforcement 

Administration. 

[FR Doc. 2010–27021 Filed 10–25–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on September 3, 2010, 

Johnson Matthey Inc., Custom 

Pharmaceuticals Department, 2003 

Nolte Drive, West Deptford, New Jersey 

08066–1742, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

a bulk manufacturer of the basic classes 

of controlled substances listed in 

schedules I and II: 

Drug Schedule 

Gamma Hydroxybutyric Acid 

(2010).

I 

Tetrahydrocannabinols (7370) ..... I 

Dihydromorphine (9145) ............... I 

Difenoxin (9168) ........................... I 

Propiram (9649) ........................... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

Nabilone (7379) ............................ II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Ecgonine (9180) ........................... II 

Hydrocodone (9193) ..................... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Methadone intermediate (9254) ... II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Oxymorphone (9652) ................... II 

Noroxymorphone (9668) .............. II 

Alfentanil (9737) ........................... II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for sale to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such a controlled 

substance, may file comments or 

objections to the issuance of the 

proposed registration pursuant to 21 

CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than December 27, 2010. 

Dated: October 19, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator,Office of 

Diversion Control,Drug Enforcement 

Administration. 

[FR Doc. 2010–27019 Filed 10–25–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on July 16, 2010, 

Chemic Laboratories, Inc., 480 Neponset 

Street, Building 7, Canton, 

Massachusetts 02021, made application 


emcdonald on DSK2BSOYB1PROD with NOTICES